Trial Profile

A Study of the Safety and Efficacy of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMM 101 (Primary) ; Nivolumab (Primary) ; Ipilimumab
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Sponsors Immodulon Therapeutics

Most Recent Events

07 Jun 2022 Final results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
06 Apr 2022 Status changed from active, no longer recruiting to completed.
12 May 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com